


LISTING OF CLAIMS:

1. (Currently Amended) A pharmaceutical aqueous suspension comprising:
 - a) a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient;
 - b) a thickener;
 - c) a uniformly dispersed nucleation inhibitor, wherein said nucleation inhibitor reduces growth rate of said active ingredient compared to suspensions not containing a nucleation inhibitor and wherein said nucleation inhibitor is polyvinylpyrrolidone;
and
 - d) at least one amino polycarboxylic acid compound;wherein the suspension has a pH of about 3.7 to about 8.
2. (Original) A suspension according to claim 1, wherein the suspended solid particles are hydrophobic and the suspension further comprises a surfactant.
3. (Original) A suspension according to claim 1, wherein the suspended solid particles have a median particle size, as measured by laser scattering, of about 1 to about 20 microns.
4. (Original) A suspension according to claim 1, wherein the suspension comprises a blend of at least a structuring agent and a swelling agent as the thickener.
5. (Original) A suspension according to claim 1, wherein the active ingredient is substantially insoluble in an aqueous environment at room temperature.
6. (Previously Presented) A suspension according to claim 1 wherein the aqueous suspension has a pH between about 3 and about 6 at room temperature.
7. (Cancelled)
8. (Previously Presented) A suspension according to claim 1 wherein the pH of the aqueous suspension remains within about 0.2 pH units for a period of at least about four weeks starting from its complete formulation when stored at a temperature of at least about 60°C.


9. (Previously Presented) A suspension according to claim 1 wherein the viscosity remains constant for at least about two weeks when stored at a temperature of at least about 60°C.

10. (Previously Presented) A suspension according to claim 1 wherein the viscosity within a range of plus or minus about 25% of its initial value for a period of at least about 8 weeks when stored at a temperature of about 60°C.

11. (Original) A suspension according to claim 1 wherein the amino polycarboxylic acid compound is a compound according to formula (I) and pharmaceutically acceptable salts thereof:



wherein R_1 and R_2 , independently of one another, are hydrogen, hydroxy-terminated C_1 - C_4 alkylene, carboxylic-terminated C_1 - C_4 alkylene or $N-[R_3OOH]_m$; and R_3 , R_4 , R_5 and R_6 are independently of one another are C_1 - C_4 alkylene and m is 1 or 2; or formula (II)



wherein R_7 , R_8 and R_9 , independently of one another, are hydrogen, C_1 - C_4 alkyl, carboxylic-terminated C_1 - C_4 alkylene or hydroxy-terminated C_1 - C_4 alkylene and pharmaceutically acceptable salts of formula (I) or (II).

12. (Original) A suspension according to claim 11, wherein at least one amino polycarboxylic acid compound is represented by formula (I) and R_1 , R_2 and R_3 are ethylene.

13. (Original) A suspension according to claim 1, wherein the amino polycarboxylic acid compound is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), hydroxyethylethylenediaminetriacetic acid, dihydroxyethylethylenediaminediacetic acid, 1,3-propanediaminetetraacetic acid, diethylenetriaminopentaacetic acid,

triethylenetetraminehexaacetic acid, iminodiacetic acid, methyliminodiacetic acid, nitrilotriacetic acid, and salts thereof, and mixtures thereof.

14. (Previously Presented) A suspension according to claim 1, wherein the amino polycarboxylic acid compound is selected from ethylenediaminetetraacetic acid, salts thereof and mixtures thereof.

15. (Original) A suspension according to claim 1, wherein the amino polycarboxylic acid compound is disodium ethylenediaminetetraacetate.

16. (Original) A suspension according to claim 11 wherein the active ingredient is an anti-histamine or analgesic.

17. (Original) A suspension according to claim 14 wherein the active ingredient is loratadine.

18. (Withdrawn) A suspension according to claim 16 wherein the active ingredient is acetaminophen or ibuprofen.

19. (Previously Presented) A pharmaceutical aqueous suspension comprising:

- a) a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient;
- b) a blended thickening component comprising xanthan gum and pre-gelatinized starch;
- c) at least one amino polycarboxylic acid compound; and
- d) polyvinylpyrrolidone;

wherein the suspension has a pH of about 3.7 to 8.

20. (Cancelled)

21. (Original) A suspension according to claim 19 further comprising a surfactant.

22. (Currently Amended) A pharmaceutical aqueous suspension comprising a therapeutically effective amount of suspended solid particles in crystal form comprising at least one active ingredient selected from the group consisting of fexofenadine, loratadine, desloratadine,

terfenadine, astemizole, norastemizole, cetirizine, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof, wherein the suspension comprises polyvinylpyrrolidone and has a pH of about 3.7 to about 8; and wherein the suspended solid particles have a median particle size, as measured by laser scattering, of about 1 to about 20 microns after about 4 weeks at about 60°C.

23. (New) A suspension of claim 1, wherein said active ingredient is loratadine.
24. (New) A suspension of claim 19, wherein said active ingredient is loratadine.
25. (New) A suspension of claim 22, wherein said active ingredient is loratadine.